Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. CSL Limited
  6. News
  7. Summary
    CSL   AU000000CSL8

CSL LIMITED

(CSL)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CSL : Update on COVID-19 Vaccine Numbers

05/01/2021 | 02:05am EDT
Update on CSL COVID-19 Vaccine Manufacturing Numbers
01 May 2021
Media Statement

Melbourne, Australia: CSL can confirm that production of the AstraZeneca COVID-19 vaccine for Australia has reached more than a million doses a week - these volumes have been produced for a number of weeks and are due to be released into the community from mid-late May following required quality checks.

To date, more than 3.7 million COVID-19 vaccines have been released from CSL and Seqirus' Australian manufacturing facilities.

To ensure that the vaccines meet the required quality standards there is approximately a four week quality control and approval process from the time vials are filled, involving a series of stringent tests conducted on each batch and undertaken by CSL, AstraZeneca and the TGA.

Manufacturing any biological product at industrial scale involves a high degree of fine-tuning to achieve optimal levels of production. The teams at CSL Behring and Seqirus have been working to improve processes and increase output, and we are pleased to now be delivering targeted volumes.

There are a number of inherent variables in production of biological products and because of this the number of doses from each batch will continue to vary - this is normal and expected.

CSL is proud of its ongoing role to support Australia's vaccination efforts and the team continues to work around the clock to produce safe and effective vaccines for the country.

- ENDS -

About CSL

CSL(ASX:CSL; USOTC:CSLLY) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL - including our two businesses, CSL Behring and Seqirus - provides life-saving products to more than 70 countries and employs more than 27,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit Vita at CSLBehring.com/Vitaand follow us on Twitter.com/CSL

For more information about CSL Limited, visit www.csl.com.au

Related News

  • share

Disclaimer

CSL Limited published this content on 01 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 May 2021 06:04:06 UTC.


ę Publicnow 2021
All news about CSL LIMITED
06/23Australia shares dragged by banks, energy stocks amid NSW virus concerns
RE
06/18Australia shares end higher on tech, healthcare boost
RE
06/09Australian shares inch higher on tech gains; U.S. inflation data eyed
RE
06/09CSLá : Hizentra (Immune Globulin Subcutaneous 20% Liquid) To Be Covered Under Me..
AQ
06/08Australia shares off record peak as focus shifts to U.S. data
RE
06/04Financials lift Aussie stocks to all-time high for third day on GDP data boos..
RE
05/31CSLá : Applications Open for Fellowships
PU
05/24Australian shares rise to two-week high as energy stocks rally
RE
05/20Tech rally, upbeat job data help Australia shares extend gains
RE
05/19Australia shares recover on financial, tech boost
RE
More news
Financials (USD)
Sales 2021 10 087 M - -
Net income 2021 2 295 M - -
Net Debt 2021 4 220 M - -
P/E ratio 2021 43,1x
Yield 2021 0,93%
Capitalization 98 913 M 98 843 M -
EV / Sales 2021 10,2x
EV / Sales 2022 9,82x
Nbr of Employees 27 000
Free-Float 99,8%
Chart CSL LIMITED
Duration : Period :
CSL Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CSL LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 217,33 $
Average target price 234,18 $
Spread / Average Target 7,75%
EPS Revisions
Managers and Directors
NameTitle
Paul Roger Perreault Chief Executive Officer, Executive Director & MD
Joy Carolyn Linton Chief Financial Officer
Brian Anthony McNamee Chairman
Andrew Cuthbertson Chief Scientific Officer & Executive Director
William Mezzanotte Chief Medical Officer, EVP & Head-R&D
Sector and Competitors
1st jan.Capitalization (M$)
CSL LIMITED1.21%101 562
WUXI BIOLOGICS (CAYMAN) INC.35.02%75 852
BIOGEN INC.51.88%55 991
SAMSUNG BIOLOGICS CO.,LTD.3.51%49 982
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.20.42%43 864
ALEXION PHARMACEUTICALS, INC.14.97%39 746